|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A polyhistidine-tag is an amino acid motif in proteins that consists of at least five histidine (His) residues, often at the N- or C-terminus of the protein.
Polyhistidine-tags are often used for affinity purification of polyhistidine-tagged recombinant proteins expressed in Escherichia coli and other prokaryotic expression systems.
|Rat TNFSF8 ORF mammalian expression plasmid, C-GFPSpark tag||RG80148-ACG|
|Rat TNFSF8 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||RG80148-ACR|
|Rat TNFSF8 ORF mammalian expression plasmid, C-Flag tag||RG80148-CF|
|Rat TNFSF8 ORF mammalian expression plasmid, C-His tag||RG80148-CH|
|Rat TNFSF8 ORF mammalian expression plasmid, C-Myc tag||RG80148-CM|
|Rat TNFSF8 ORF mammalian expression plasmid, C-HA tag||RG80148-CY|
|Rat TNFSF8 Gene cDNA clone plasmid||RG80148-G|
|Rat TNFSF8 ORF mammalian expression plasmid, N-Flag tag||RG80148-NF|
|Rat TNFSF8 ORF mammalian expression plasmid, N-His tag||RG80148-NH|
|Rat TNFSF8 ORF mammalian expression plasmid, N-Myc tag||RG80148-NM|
|Rat TNFSF8 ORF mammalian expression plasmid, N-HA tag||RG80148-NY|
|Rat TNFSF8 natural ORF mammalian expression plasmid||RG80148-UT|
|Learn more about expression Vectors|
CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.